However, no clear evidence of benefit for PTEN‐null cancer patients treated with PI3K inhibitors in clinics has been reported to date (Kim et al, 2017; Martin et al, 2017) and, despite the urgent need of a targeted treatment for this subset of poor prognosis patients, the molecular bases for the lack of efficacy of those therapies are still poorly understood. The gene discussed is PIK3CD; the disease is cancer.